SI2992016T1 - Kombinirano zdravljenje afukoziliranega protitelesa CD20 s konjugatom protitelesa CD79b in zdravila - Google Patents

Kombinirano zdravljenje afukoziliranega protitelesa CD20 s konjugatom protitelesa CD79b in zdravila Download PDF

Info

Publication number
SI2992016T1
SI2992016T1 SI201430518T SI201430518T SI2992016T1 SI 2992016 T1 SI2992016 T1 SI 2992016T1 SI 201430518 T SI201430518 T SI 201430518T SI 201430518 T SI201430518 T SI 201430518T SI 2992016 T1 SI2992016 T1 SI 2992016T1
Authority
SI
Slovenia
Prior art keywords
cd79b
antibody
cancer
treatment
cd79b antibody
Prior art date
Application number
SI201430518T
Other languages
English (en)
Inventor
Christian Klein
Sabine Lang
Andrew G. Polson
Pablo Umana
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI2992016T1 publication Critical patent/SI2992016T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (6)

  1. Kombinirano zdravljenje afukoziliranega protitelesa CD20 s konjugatom protitelesa CD79b in zdravila Patentni zahtevki
    1. Obinutuzumab za uporabo pri zdravljenju raka v kombinaciji s konjugatom protitelesa CD79b in zdravila anti-CD79b-MC-vc-PAB-MMAE, pri čemer protitelo anti-CD79b v omenjenem konjugatu protitelesa CD79b in zdravila predstavlja huMA79b.v28, ki vključuje variabilno domeno lahke verige z identifikacijsko številko zaporedja 69 ter variabilno domeno na težki verigi z identifikacijsko številko zaporedja 70.
  2. 2. Obinutuzumab za uporabo po zahtevku 1 pri zdravljenju raka v kombinaciji s konjugatom protitelesa CD79b in zdravila anti-CD79b-MC-vc-PAB-MMAE, označen s tem, da se uporablja tudi eno ali več dodatnih citotoksičnih, kemoterapevtskih ali protirakavih učinkovin ali spojin ali ionizirajoče obsevanje, ki povečajo učinek takih sredstev.
  3. 3. Obinutuzumab za uporabo po zahtevku 1 ali 2 za zdravljenje raka v kombinaciji s konjugatom protitelesa CD79b in zdravila anti-CD79b-MC-vc-PAB-MMAE, označen s tem, da omenjeni rak izraža CD20.
  4. 4. Obinutuzumab za uporabo po zahtevku 3 za zdravljenje raka v kombinaciji s konjugatom protitelesa CD79b in zdravila anti-CD79b-MC-vc-PAB-MMAE, označen s tem, daje omenjeni rak, ki izraža CD20, limfom ali limfocitna levkemija.
  5. 5. Sestavek za uporabo pri zdravljenju raka, ki jo sestavlja obinutuzumab in konjugat protitelesa CD79b ter zdravila anti-CD79b-MC-vc-PAB-MMAE, pri čemer protitelo anti-CD79b v omenjenem konjugatu protitelesa CD79b in zdravila predstavlja huMA79b.v28, ki vključuje variabilno domeno na lahki verigi z identifikacijsko številko zaporedja 69 ter variabilno domeno na težki verigi z identifikacijsko številko zaporedja 70.
  6. 6. Zmes za uporabo pri zdravljenju raka po zahtevku 5, označena s tem, da se uporablja tudi eno ali več dodatnih citotoksičnih, kemoterapevtskih ali protirakavih učinkovin ali spojin ali ionizirajoče obsevanje, ki povečajo učinek takih sredstev.
SI201430518T 2013-05-02 2014-04-30 Kombinirano zdravljenje afukoziliranega protitelesa CD20 s konjugatom protitelesa CD79b in zdravila SI2992016T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361818821P 2013-05-02 2013-05-02
EP14724662.3A EP2992016B1 (en) 2013-05-02 2014-04-30 Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate
PCT/EP2014/058827 WO2014177615A2 (en) 2013-05-02 2014-04-30 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE

Publications (1)

Publication Number Publication Date
SI2992016T1 true SI2992016T1 (sl) 2018-01-31

Family

ID=50733021

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201430518T SI2992016T1 (sl) 2013-05-02 2014-04-30 Kombinirano zdravljenje afukoziliranega protitelesa CD20 s konjugatom protitelesa CD79b in zdravila

Country Status (27)

Country Link
US (4) US20140356352A1 (sl)
EP (1) EP2992016B1 (sl)
JP (1) JP6306154B2 (sl)
KR (1) KR101824311B1 (sl)
CN (1) CN105189558A (sl)
AR (1) AR096183A1 (sl)
AU (1) AU2014261454B2 (sl)
BR (1) BR112015027309A2 (sl)
CA (1) CA2908658C (sl)
DK (1) DK2992016T3 (sl)
ES (1) ES2653424T3 (sl)
HK (1) HK1213575A1 (sl)
HR (1) HRP20171897T1 (sl)
HU (1) HUE035171T2 (sl)
IL (1) IL242163B (sl)
LT (1) LT2992016T (sl)
MX (1) MX359964B (sl)
MY (1) MY181960A (sl)
NO (1) NO3080382T3 (sl)
NZ (1) NZ713745A (sl)
PL (1) PL2992016T3 (sl)
PT (1) PT2992016T (sl)
RS (1) RS56688B1 (sl)
RU (1) RU2670971C9 (sl)
SG (1) SG11201509009WA (sl)
SI (1) SI2992016T1 (sl)
WO (1) WO2014177615A2 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104650230A (zh) * 2008-01-31 2015-05-27 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
EP3262071B8 (en) 2014-09-23 2022-05-18 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
KR102850929B1 (ko) * 2015-12-09 2025-08-27 에프. 호프만-라 로슈 아게 항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
US20170315132A1 (en) * 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
US20180140703A1 (en) * 2016-11-18 2018-05-24 The Regents Of The University California Tumor radiosensitization with antibody conjugates
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CR20250325A (es) * 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
US12365730B2 (en) 2019-01-28 2025-07-22 Tuojie Biotech (Shanghai) Co., Ltd. Anti-CD79B antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN112094345B (zh) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 可应用于肿瘤细胞捕获的小鼠抗免疫球蛋白关联βCD79b的单克隆抗体
KR20230044275A (ko) * 2020-07-27 2023-04-03 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 항-cd79b 항체-약물 접합체, 및 이의 제조 방법 및 이의 약학적 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6922984B2 (en) * 2003-08-27 2005-08-02 Valero Refining Company - California Heat recovery circuit
BRPI0416262B1 (pt) 2003-11-05 2022-04-12 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
ES2382627T3 (es) * 2004-06-29 2012-06-12 B.R.A.H.M.S Gmbh Nuevos anticuerpos monoclonales estimuladores o bloqueadores de la tiroides, secuencias peptídicas que corresponden a sus regiones variables, y sus usos en medicina diagnóstica, preventiva y terapéutica
CL2008002085A1 (es) * 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
CN104650230A (zh) * 2008-01-31 2015-05-27 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法

Also Published As

Publication number Publication date
IL242163B (en) 2019-08-29
RU2670971C2 (ru) 2018-10-26
WO2014177615A2 (en) 2014-11-06
AU2014261454B2 (en) 2019-03-14
CA2908658A1 (en) 2014-11-06
HK1213575A1 (zh) 2016-07-08
US20180344848A1 (en) 2018-12-06
RS56688B1 (sr) 2018-03-30
US20140356352A1 (en) 2014-12-04
MY181960A (en) 2021-01-15
ES2653424T3 (es) 2018-02-07
MX359964B (es) 2018-10-17
CN105189558A (zh) 2015-12-23
HRP20171897T1 (hr) 2018-01-12
DK2992016T3 (en) 2018-01-02
BR112015027309A2 (pt) 2017-09-26
NO3080382T3 (sl) 2018-05-26
AU2014261454A1 (en) 2015-11-12
KR101824311B1 (ko) 2018-01-31
US20210138065A1 (en) 2021-05-13
AR096183A1 (es) 2015-12-16
JP6306154B2 (ja) 2018-04-04
MX2015015091A (es) 2016-02-11
EP2992016A2 (en) 2016-03-09
JP2016520049A (ja) 2016-07-11
KR20160003841A (ko) 2016-01-11
LT2992016T (lt) 2018-01-10
PL2992016T3 (pl) 2018-02-28
EP2992016B1 (en) 2017-10-18
RU2015151454A (ru) 2017-06-07
NZ713745A (en) 2019-08-30
PT2992016T (pt) 2017-12-18
WO2014177615A3 (en) 2014-12-24
HUE035171T2 (en) 2018-05-02
RU2670971C9 (ru) 2018-11-22
SG11201509009WA (en) 2015-12-30
CA2908658C (en) 2020-02-18
US20180133315A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
SI2992016T1 (sl) Kombinirano zdravljenje afukoziliranega protitelesa CD20 s konjugatom protitelesa CD79b in zdravila
BRPI0909227B8 (pt) uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)
CY1123606T1 (el) Συζευγματα αντισωματων που εχουν τροποποιηθει με κυστεϊνη
CY1121870T1 (el) Anti-egfrviii αντισωματα και χρησεις αυτων
CL2016000318A1 (es) Compuestos de conjugado anticuerpo-fármaco dimérico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y métodos de uso y tratamiento
CR20190266A (es) Anticuerpos anti-tim-3 para combinar con anticuerpos anti-pd-1
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
CY1119324T1 (el) Αντισωματα εναντιον csf-1r
MX391786B (es) Anticuerpos anti-met, moleculas de unión a antígeno biespecificas que se unen a met y métodos de uso de los mismos.
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
CY1125181T1 (el) Ανοσοσυζευγματα που στοχευουν adam9 και μεθοδοι χρησης αυτων
EA202091161A1 (ru) Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения
ZA201706745B (en) Site-specific antibody-drug conjugates
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
EA201791461A1 (ru) Бензодиазепиновые димеры с мостиковым гетероариленом, их конъюгаты, способы получения и применение
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
PH12016500349B1 (en) Anti-prlr antibodies and uses thereof
EA201691963A1 (ru) Производные тубулизина
BR112016013861A2 (pt) conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
SG10201811124YA (en) Her2 antibody-drug conjugates
BR112017011111A2 (pt) conjugados de pirrolobenzodiazepina-anticorpo
MX370829B (es) Uso de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd22-fármaco.
MX2016007578A (es) Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.